Mahesh Karande Receives Stock Award at Omega Therapeutics Inc (OMGA) — SEC Form 4, Mar 11, 2022
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Mahesh Karande CIK 0001860422 |
Director
CEO
|
Mahesh Karande at Omega Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Omega Therapeutics Inc
| 2024-02-09 | Award | — | View |
| 2023-03-02 | Award | — | View |
| 2022-10-28 | Award | — | View |
| 2022-02-03 | Exercise | — | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Option (Right to Buy)F1 | $10.34 | 2022-03-09 | A - Award/Grant | 340,000 A | $0.00 | 2032-03-08 | 340,000 Common Stock | Direct |
Footnotes (1)
- F1
- The options vest and become exercisable with respect to 25% of the underlying shares on March 9, 2023 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on March 9, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Show more
Related filings at Omega Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
1
institutional managers reporting a position
Largest by reported value
5%+ Holders · 13D/G
2 filers
Other insiders at Omega Therapeutics Inc
GET /v1/forms/4/0000899243-22-010694
API docs
View Original SEC Filing